Phase 1 Single Dose Escalation/Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, And Pharmacokinetics of Ascending Doses of a MEK Inhibitor (ATR-002) Given for 7 Days in Healthy Subjects

Atriva Therapeutics GmbH1 site in 1 country70 target enrollmentApril 24, 2019

ConditionsInfluenza

InterventionsATR-002 MEK Inhibitor Placebo oral tablet

DrugsATR-002 MEK Inhibitor Placebo oral tablet

Overview

Phase: Phase 1
Intervention: ATR-002 MEK Inhibitor
Conditions: Influenza
Sponsor: Atriva Therapeutics GmbH
Enrollment: 70
Locations: 1
Primary Endpoint: Treatment-emergent adverse events (TEAE) - SAD
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This was a combination of a single ascending dose (SAD) study to evaluate the safety, tolerability, and PK of 3 oral doses of a MEK inhibitor and a multiple ascending dose (MAD) study of 3 oral doses of a MEK inhibitor.

Subjects were to be enrolled in 3 different cohorts in the SAD and 3 different cohorts in the MAD and were to be randomly (blinded) allocated to active treatment or placebo (each cohort consisted of 8 subjects receiving active treatment and 2 subjects receiving placebo).

Detailed Description

Each subject in the SAD cohorts was to receive a single dose of the MEK inhibitor ATR-002 (PD0184264), with a starting dose of 100 mg ATR-002 or placebo: * Cohort 1: 100 mg ATR-002 or placebo; * Cohort 2: 100 mg + X mg ATR-002 or placebo; * Cohort 3: 100 mg + X mg + Y mg ATR-002 or placebo. An additional cohort (Cohort 4) of 10 subjects (4:1 active vs placebo) could have been recruited into the SAD Part, if appropriate. Effectively, 4 cohorts were treated: * Cohort 1: 100 mg ATR-002 or placebo; * Cohort 2: 300 mg ATR-002 or placebo; * Cohort 3: 600 mg ATR-002 or placebo; * Cohort 4: 900 mg ATR-002 or placebo. Between each cohort, a blinded interim analysis of PK, safety and tolerability had to be performed. The available data was evaluated by the Investigator and sponsor in a Safety Review Committee (SRC) meeting. Once a dose level was judged to be safe, the SRC determined the dose level for the next cohort considering a maximal increment of 400 mg compared to the previous cohort, and the next dose level could be administered to the next cohort. The maximal dose level could not exceed 900 mg ATR-002. Each subject in the MAD cohorts was to receive once daily (QD) doses (fasted) of the MEK inhibitor ATR-002 for 7 days, starting with a dose of 100 mg ATR-002 or placebo QD. * Cohort 5: 100 mg ATR-002 QD or placebo; * Cohort 6: 100 mg + A mg ATR-002 QD or placebo; * Cohort 7: 100 mg + A mg + B mg ATR-002 QD or placebo. An additional cohort (Cohort 8) of 10 subjects (4:1 active vs placebo) could be recruited into the MAD Part, if appropriate. Effectively, 3 cohorts were treated: * Cohort 5: 100 mg ATR-002 QD or placebo; * Cohort 6: 300 mg ATR-002 QD or placebo; * Cohort 7: 600 mg ATR-002 QD or placebo. Between each cohort, a blinded interim analysis of PK, safety and tolerability had to be performed. The available data was evaluated by the Investigator and sponsor in a SRC meeting. Once a dose level was judged to be safe, the SCR determined the dose level for the next cohort considering a maximal increment of 400 mg compared to the previous cohort, and the next dose level could be administered to the next cohort. The maximal dose level could not exceed 900 mg ATR-002. During the study, no repeated daily dose could exceed the maximum single dose that has been shown to cause no safety concerns. Subjects were resident on the ward from the day (late afternoon/evening) before dosing (Day -1) until completion of procedures at 96h following their final dose of study medication. They were to attend a follow up visit 28 days (± 2 days) following their final dose of study medication. Subjects with AEs that were ongoing at the end of the study were followed up as appropriate until the AEs had resolved or stabilised, up to a maximum of 30 days after the last dose of study drug. Pharmacokinetics were determined predose 30 min, 1h, 2h, 4h, 8h, 12h, and 24h, postdose, and predose on Day 2-4 in the SAD Part, and predose 30 min, 1h, 2h, 4h, 8h, 12h, and 24h, of Day 1 and Day 7, predose on Day 2-6 and 48h, 72h, and 96h post final dose of Day 7 in the MAD Part. The 72h and 96h samples in both SAD and MAD were only to be analysed if deemed informative based on the results of the 48h PK sample.

Registry

clinicaltrials.gov

Start Date

April 24, 2019

End Date

August 26, 2019

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Atriva Therapeutics GmbH

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Male or female, between 18 and 55 years old, extremes included;
•Weighed at least 50 kg and had a body mass index (BMI) within normal range: 18.0≤ BMI \<31.0 kg/m2;
•In good physical and mental health as determined on the basis of medical history and general physical examination performed at screening;
•Haematology and chemistry parameters, pulse rate and/or blood pressure, and ECG within the reference range for the population studied, or showing no clinically relevant deviations, as judged by the Investigator;
•Negative urine test for selected drugs of abuse at screening and upon check-in at the clinical site; Note: Subjects could not consume poppy-seeds within 24h before screening and before each urine drug screening because this could falsify the results of the opiate urine drug test.
•Negative alcohol breath test at screening and upon check-in at the clinical site;
•Negative hepatitis panel (including hepatitis B surface antigen \[HBsAg\] and anti hepatitis C virus \[HCV\] antibodies) and negative human immunodeficiency virus (HIV) antibody screens;
•Female subjects had to be of non-childbearing potential, as follows:
•At least 1 year post-menopausal (amenorrhea \>12 months in the absence of an alternative medical cause and follicle-stimulating hormone \>30 mIU/mL in women not using hormonal contraception or hormonal replacement therapy) prior to screening;
•Surgically sterile (bilateral oophorectomy, hysterectomy, bilateral salpingectomy, or bilateral tubal ligation);

Exclusion Criteria

•Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-study screening assessment that could interfere with the objectives of the study or the safety of the subject;
•Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the subject's participation in the study or make it unnecessarily hazardous;
•A condition that, in the opinion of the Investigator, could compromise the well being of the subject or course of the study, or prevent the subject from meeting or performing any study requirements;
•Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease, cancer, or history of any psychotic mental illness;
•Respiratory tract infection within 4 weeks before the screening visit;
•History of surgery or medical intervention, or planned surgery or medical intervention, that could interfere with the objectives of the study or the safety of the subject;
•Presence or history of severe adverse reaction to any drug, or sensitivity to components of the study medication;
•Use of a prescription or over-the-counter medicine, with the exception of acetaminophen (paracetamol), during the 7 days (or 5 half-lives, whichever is longer) before the first dose of study medication;
•Participation in another clinical study of a new chemical entity, new device, or a prescription medicine within the 3 months before dosing, or participation within 5 half-lives of receiving an experimental drug (whichever is longer);
•Presence or history of drug or alcohol abuse, or intake of more than 21 units (14 units for women) of alcohol weekly;